Clinical Trial Update: Immunotherapy With E6 T Cell Receptor (TCR) T Cells for Vulvar High-Grade Squamous Intraepithelial Lesions [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating E6 TCR-T cells for vulvar high-grade squamous intraepithelial lesions associated with HPV-16; study terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hpv-16-associated Disease
• Human Papillomavirus-related Disease
• Vulvar High-grade Squamous Intraepithelial Lesion

Drugs mentioned

• E6 TCR-T cells (E6 TCR-T cells)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Human Papillomavirus, HPV-16 | Phase 1 | Status: TERMINATED | Results posted: 2019-10-08